Consider the Bear Case Scenario for Boston Scientific (NYSE:BSX) Certain studies show a small, but potentially fatal, blood clot side effect associated with the long-term use of drug-eluting stents. Patient pool is limited to those tolerating longer-term use of blood-thinning medications. Tough Gig. Profitability continues to trail that of its rivals thanks to a broad portfolio that includes lower-margin products.
George Gutowski writes from a caveat emptor perspective.